OTLK Outlook Therapeutics, Inc.: Rasio nilai perusahaan marang pendapatan

Outlook Therapeutics Inc (OTLK) - logo korporat

Independence from macroeconomics makes biotechnology a defensive asset, meaning changes in the EV/Sales ratio clearly capture the market valuation of the business. The current 0.00 figure expresses the state of the enterprise value-to-revenue metric. A lack of recurring revenue makes Outlook Therapeutics (OTLK) dependent on investments and regulatory approvals, while a strong scientific team is retained through stock options and a high social mission.

Outlook Therapeutics, Inc. (OTLK): Rasio nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

Rincian metrik keuangan lan pasar Outlook Pharma (OTLK)

- rega saham lan target rega konsensus:
Pambiji fundamental:Outlook Therapeutics (OTLK)
Produk seri Outlook Therapeutics Inc

The EV/Sales chart dynamics reflect market expectations for the global expansion of Outlook Therapeutics (OTLK) ophthalmic drug, offsetting regulatory risks through geographic reach. This indicator compares the total enterprise value, adjusted for net debt, against revenue, allowing investors to assess the real value of assets without distortions from financial leverage and determine whether the company is overbought or undervalued.